1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | On 07/23/2024, Licensing Program Analysts (LPAs) Arielle Pascua and Pang Lee arrived unannounced to conduct a case management visit. LPAs met with Facility Designated Administrator (FDA), Kathleen Gilbey and explained the purpose of the visit.
The purpose of this visit was to follow up on an incident report received by the department on 06/29/2024.
On 06/23/2024, the department received an LIC 624 incident report that occurred on 06/23/2024 regarding resident 1 (R1). LPA reviewed the incident report, and it was learned that on 06/23/2024, during an internal community medication audit, it was noted that (R1)’s Megestrol Acetate 40 mg with directions of take 2 tablets by mouth 2 times daily for 3 weeks was not given to resident from 06/03/2024 to 06/06/2024, 06/12/2024 to 06/20/2024 for a total of 12 days.
Furthermore, the incident report dated on 06/29/2024 states that R1 was diagnosed by a home health nurse that they have an unstageable wound on 06/20/2024 at 5:30pm and sent to UC Davis hospital for further evaluation on 06/21/2024.
Based on record review, this incident report was faxed to the department on 06/29/2024, however the incident occurred on 06/20/2024 and 06/21/2024. As a result, the facility did not follow the reporting requirements.
LPA obtained facility records. Due to insufficient time to review documentation and conduct interviews the department will come at a later date to follow up on the incident reported on 06/29/2024.
The following deficiencies were observed and cited from the California Code of Regulations, Title 22, and California Health and Safety Code. The deficiencies can be found on the 809-D page.
An exit was interview conducted, and a copy of the 809 report, 809-D page, and appeal rights were given to the facility. |